Information Provided By: 
Fly News Breaks for December 16, 2016
CNC
Dec 16, 2016 | 07:49 EDT
Oppenheimer analyst Michael Wiederhorn notes that Centene's guidance was likely slightly lower than expected, but says it is explained by the 20c/share impact of the Exchange business. Nonetheless, the analyst continues to favor Centene due to its growth outlook and attractive valuation, and would continue to be a buyer on any volatility. He reiterates an Outperform rating and $89 price target on the shares.
News For CNC From the Last 2 Days
CNC
Apr 15, 2024 | 10:37 EDT
Shares of health care facilities and managed care are in the spotlight on Monday after Florida announced late on Friday five winners of six-year Medicaid managed care contracts. Among the winners... To see the rest of the story go to thefly.com. See Story Here
CNC
Apr 15, 2024 | 09:56 EDT
CNC
Apr 15, 2024 | 09:47 EDT
CNC
Apr 15, 2024 | 06:16 EDT
CNC
Apr 15, 2024 | 06:15 EDT
Wells Fargo raised the firm's price target on Centene (CNC) to $93 from $89 and keeps an Overweight rating on the shares. The firm notes Florida intends to award Medicaid contracts to Centene, Elevance Health (ELV), Humana (HUM) and two provider-run plans. Clearly the most positive for Centene given recent disappointing RFP performance and likely most disappointing for Molina Healthcare (MOH) given expectation for share gains, Wells says.
